they are aiming to finish cohort 4 by end of calendar year, but that is contingent on the other two trial sites opening up.
but cohort 3 will be this year, SNO (cohort 1 was presented there in Nov21- largest neurology conference in the US) in Nov would be an ideal time for cohort 4 or at minimum cohort 3 with follow up. and imo if they see something beyond disease control… they may not wait for the whole cohort to be dosed to release something.
CHM Price at posting:
15.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)